Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 23 (August 10), 2007: pp. 3456-3461
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.2144

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saltz, L. B.
Right arrow Articles by Mayer, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saltz, L. B.
Right arrow Articles by Mayer, R. J.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803

Leonard B. Saltz, Donna Niedzwiecki, Donna Hollis, Richard M. Goldberg, Alexander Hantel, James P. Thomas, Anthony L.A. Fields, Robert J. Mayer

From the Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; Departments of Medicine and Biostatistics, Duke University, Durham; Department of Medicine, University of North Carolina, Chapel Hill, NC; Department of Medicine, Loyola University, Chicago, IL; Department of Medicine, University of Wisconsin, Madison, WI; Department of Medicine, University of Alberta, Alberta, Canada; and the Dana-Farber Cancer Institute, Boston, MA

Address reprint requests to Leonard Saltz, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: saltzl{at}mskcc.org

Purpose Randomized studies have shown that irinotecan (CPT-11) extends survival in metastatic colorectal cancer patients when administered in second-line and when added to fluorouracil (FU) plus leucovorin (LV) in first-line therapy of metastatic colorectal cancer. When this study was initiated, FU plus LV was standard adjuvant treatment for stage III colon cancer. We evaluated the efficacy and safety of weekly bolus CPT-11 plus FU plus LV in the treatment of patients with completely resected stage III colon cancer.

Methods A total of 1,264 patients were randomly assigned to receive either standard weekly bolus FU plus LV regimen or weekly bolus CPT-11 plus FU plus LV. The primary end points of the study were overall survival (OS) and disease-free survival (DFS).

Results Treatment arms were well-balanced for patient characteristics and prognostic variables. There were no differences in either DFS or OS between the two treatment arms. Toxicity, including lethal toxicity, was significantly higher on the CPT-11 plus FU plus LV arm.

Conclusion The addition of CPT-11 to weekly bolus FU plus LV did not result in improvement in DFS or OS in stage III disease, but did increase both lethal and nonlethal toxicity. This trial demonstrates that advances in the treatment of metastatic disease do not necessarily translate into advances in adjuvant treatment, and it reinforces the need for randomized controlled adjuvant studies.

Supported by National Cancer Institute Grant No. 2 U10 CA33601-25.

Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology Meeting, June 5-8, 2004, New Orleans, LA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • A Renewed Call for Equipoise
    Neal J. Meropol
    JCO 2007 25: 3392-3394 [Full Text]


This article has been cited by other articles:


Home page
The OncologistHome page
R. M. Goldberg, D. J. Sargent, R. F. Morton, E. Green, H. K. Sanoff, H. McLeod, and J. Buckner
NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial
Oncologist, October 1, 2009; 14(10): 970 - 978.
[Abstract] [Full Text] [PDF]


Home page
J Oncol PractHome page
S. Y. Zafar, J. E. Marcello, J. L. Wheeler, K. L. Rowe, M. A. Morse, J. E. Herndon II, and A. P. Abernethy
Longitudinal Patterns of Chemotherapy Use in Metastatic Colorectal Cancer
J. Oncol. Pract, September 1, 2009; 5(5): 228 - 233.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Van Cutsem, R. Labianca, G. Bodoky, C. Barone, E. Aranda, B. Nordlinger, C. Topham, J. Tabernero, T. Andre, A. F. Sobrero, et al.
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
J. Clin. Oncol., July 1, 2009; 27(19): 3117 - 3125.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. J. O'Connell
Oxaliplatin or Irinotecan As Adjuvant Therapy for Colon Cancer: The Results Are In
J. Clin. Oncol., July 1, 2009; 27(19): 3082 - 3084.
[Full Text] [PDF]


Home page
JCOHome page
M. M. Bertagnolli, D. Niedzwiecki, C. C. Compton, H. P. Hahn, M. Hall, B. Damas, S. D. Jewell, R. J. Mayer, R. M. Goldberg, L. B. Saltz, et al.
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
J. Clin. Oncol., April 10, 2009; 27(11): 1814 - 1821.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Ychou, J.-L. Raoul, J.-Y. Douillard, S. Gourgou-Bourgade, R. Bugat, L. Mineur, F. Viret, Y. Becouarn, O. Bouche, E. Gamelin, et al.
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
Ann. Onc., April 1, 2009; 20(4): 674 - 680.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. M. Bertagnolli, R. S. Warren, D. Niedzwiecki, E. Mueller, C. C. Compton, M. Redston, M. Hall, H. P. Hahn, S. D. Jewell, R. J. Mayer, et al.
p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803
Clin. Cancer Res., March 15, 2009; 15(6): 2116 - 2122.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Sargent, A. Sobrero, A. Grothey, M. J. O'Connell, M. Buyse, T. Andre, Y. Zheng, E. Green, R. Labianca, C. O'Callaghan, et al.
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
J. Clin. Oncol., February 20, 2009; 27(6): 872 - 877.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. A. Meyerhardt, D. Niedzwiecki, D. Hollis, L. B. Saltz, R. J. Mayer, H. Nelson, R. Whittom, A. Hantel, J. Thomas, and C. S. Fuchs
Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803
J. Clin. Oncol., September 1, 2008; 26(25): 4109 - 4115.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. A. Chan, J. A. Meyerhardt, D. Niedzwiecki, D. Hollis, L. B. Saltz, R. J. Mayer, J. Thomas, P. Schaefer, R. Whittom, A. Hantel, et al.
Association of Family History With Cancer Recurrence and Survival Among Patients With Stage III Colon Cancer
JAMA, June 4, 2008; 299(21): 2515 - 2523.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
B. Pasche
Familial Colorectal Cancer: A Genetics Treasure Trove for Medical Discovery
JAMA, June 4, 2008; 299(21): 2564 - 2565.
[Full Text] [PDF]


Home page
Ann OncolHome page
A. Berglund, B. Cedermark, and B. Glimelius
Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?
Ann. Onc., February 1, 2008; 19(2): 400 - 402.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Grothey
Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?
Clin. Cancer Res., November 15, 2007; 13(22): 6909s - 6912s.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B. Benson III
New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease
Clin. Cancer Res., November 15, 2007; 13(22): 6913s - 6920s.
[Abstract] [Full Text] [PDF]


Home page
JWatch Oncology and HematologyHome page
Irinotecan Adds No Benefit to Adjuvant Chemotherapy in Colon Cancer Patients
Journal Watch Oncology and Hematology, October 16, 2007; 2007(1016): 1 - 1.
[Full Text]


Home page
JCOHome page
N. J. Meropol
A Renewed Call for Equipoise
J. Clin. Oncol., August 10, 2007; 25(23): 3392 - 3394.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online